Disclosures for "Functional Improvement in Patients With Myasthenia Gravis Following GLP-1/GIP Receptor Agonist Therapy: A Case Series"
-
Ms. Guerra Hernandez has nothing to disclose.
-
Ms. Farias has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx. Ms. Farias has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for UCB Biophrama. Ms. Farias has received personal compensation in the range of $500-$4,999 for serving as a Consultant for POCN. Ms. Farias has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CSL Behring. Ms. Farias has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Argenx. Ms. Farias has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for UCB Biopharma. Ms. Farias has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for CSL Behring. Ms. Farias has a non-compensated relationship as a Member with AANEM AAP Education Commitee that is relevant to AAN interests or activities. Ms. Farias has a non-compensated relationship as a Member with NEALS APP Committee that is relevant to AAN interests or activities.
-
Dr. Murray has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint .
-
The institution of Dr. Chen has received research support from Healey Center at Massachusetts General Hospital. The institution of Dr. Chen has received research support from General Hospital Corporation. The institution of Dr. Chen has received research support from Argenx.
-
Dr. Gooch has received publishing royalties from a publication relating to health care. Dr. Gooch has received publishing royalties from a publication relating to health care.
-
Dr. Vu has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Dianthus. Dr. Vu has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Vu has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NMD Pharma. Dr. Vu has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ARGENX. Dr. Vu has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Vu has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Vu has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen (Horizon). Dr. Vu has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Johnson & Johnson. Dr. Vu has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Alexion. Dr. Vu has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for CSL Behring. Dr. Vu has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Argenx. The institution of Dr. Vu has received research support from CSL Behring. The institution of Dr. Vu has received research support from Alexion. The institution of Dr. Vu has received research support from RA Pharma/UCB. The institution of Dr. Vu has received research support from Mass Gen Hospital/Healy Platform Study. The institution of Dr. Vu has received research support from ARGENX. The institution of Dr. Vu has received research support from Horizon/Amgen. The institution of Dr. Vu has received research support from Woolsey Pharma. The institution of Dr. Vu has received research support from CSL Behring. The institution of Dr. Vu has received research support from Cartesian Therapeutics. The institution of Dr. Vu has received research support from Janssen/Johnson & Johnson. The institution of Dr. Vu has received research support from Immunovant. The institution of Dr. Vu has received research support from Regeneron. The institution of Dr. Vu has received research support from Dianthus. The institution of Dr. Vu has received research support from COUR.